In vitro experiments with fibres

	<i>Dosage used</i>		<i>Observations after 24 months exposure 5 h/day; 5 days/week</i>
<i>Reference</i>	<i>Mass</i>	<i>Fibre number</i>	
<i>The experiments carried out</i>			
MMVF10 (2)	30 mg/m ³	232 f/ml	Wagner PGS 2.5 to 3
MMVF11 (2)	30 mg/m ³	246 f/ml	Wagner PGS 2.5 to 3
RCF (2)	30 mg/m ³	187 f/ml	Wagner PGS 4 Lung tumours 16 (13.0%) Mesothelioma 2 (1.6%)
Aramid (3)	Not stated	100 f/ml	Fibrosis and cystic keratinising squamous tumours
Chrysotile (2)	10 mg/m ³	10 600 f/ml	Wagner PGS 4 Lung tumours 13 (18%) Mesothelioma 1 (1.4%)
<i>The experiment that was never carried out</i>			
Chrysotile	0.18 mg/m ³	200 f/ml	?

Wagner PGS = Wagner Pathology Grading Scale as follows: Cellular changes 1 normal; 2 minimal: macrophage response; 3 mild: inflammation, bronchiolisation. Fibrosis 4 minimal: minimal fibrosis; 5 mild: linking fibrosis; 6 moderate: consolidation; 7 severe: marked fibrosis and consolidation; 8 severe: complete obstruction of most airways.

Environmental Health Sciences workshop on fibre toxicology indicates that "A major failing of past experimental studies has been the use of mass as the main dose parameter. Data are needed on fibre comparison by fiber number... Most studies using fibers in vitro have in the past expressed dosage on the basis of fiber mass as opposed to number of fibers per cell, which now appears to be a more valid means of comparison of fiber effects in relation to their potential to cause human disease."

Without going further into the details of the dosages used and the results reported, these studies indicate that the time has come to revisit the case of chrysotile asbestos, and to compare its health related effects with those of other man made fibres, with fibre number at comparable dosage for comparisons. Some surprises might be revealed from such a comprehensive re-examination of the data. A major international re-evaluation of the case of chrysotile asbestos is in order.

JACQUES DUNNIGAN
University of Sherbrooke,
Sherbrooke (Québec),
Canada J1K 2R1.

- Liddell FDK, McDonald AD, McDonald JC. The 1891-20 birth cohort of Quebec chrysotile miners and millers: a preliminary report on mortality to 1988. *9th International Symposium, Epidemiology in Occupational Health, Cincinnati, September 1992.*
- Hesterberg TW, Miller WC, McConnell EE, Chevalier J, Hadley JG, Bernstein DM, Thevenaz P, Anderson R. Chronic inhalation toxicity of size-separated glass fibers in

Fischer 344 rats. *Fund Appl Toxicol* 464-476.

- International Labour Office. *Safety in the use of mineral and synthetic fibres*: Geneva; ILO, 1990. (Occupational Safety and Health Series No 64.)
- Palekar LD, Most BM, Coffin DL. Significance of mass and number of fibers in the correlation of V79 cytotoxicity with tumorigenic potential of mineral fibers. *Environ Res* 1988;46:142-52.
- Coffin DL, Cook PM, Creason JP. Relative mesothelioma induction in rats by mineral fibers: comparison with residual pulmonary mineral fiber number and epidemiology. *Inhal Toxicol* 1992;4:273-300.
- Dement JM. Overview: workshop on fiber toxicology-research needs. *Environ Health Perspect* 1990;88:261-8.

Pulmonary effects of exposure to fine fibreglass: irregular opacities and small airways obstruction

Sir,—On behalf of the North American Insulation Manufacturers Association (NAIMA), I am writing to express our concern over the publication of an article by Kilburn *et al* (1992;49:714-20) that examined a group of fibreglass workers at an appliance manufacturing plant in Cicero, Illinois. The study concluded that "commercial rotary spun fibreglass used for insulating appliances appears to produce human disease that is similar to asbestosis."

The fact is that the conclusion of Kilburn *et al* is incorrect; fibreglass has not been found to produce human disease similar to asbestosis. Kilburn *et al* reached their conclusion despite several factors in their study that point to other culprits. For

example, at least 40% of the workers with positive findings had known exposure to asbestos. In fact, the levels of airborne asbestos reported to Kilburn *et al* by the plant were higher than the levels of glass fibres, and yet were not even considered by Kilburn *et al* in reaching their conclusion. Further, about 80% of the study participants with positive findings were current or former smokers. Finally, the x ray film and pulmonary changes Kilburn *et al* reported as abnormal are actually consistent with those that other scientists have reported to be expected in this age and type of population.

NAIMA would like to point out that the findings of Kilburn *et al* are not consistent with other morbidity studies regarding the health effects of exposure to fibreglass. Recently, Weill of Tulane University Medical School completed a study of over 1250 current workers at five US manufacturing plants. Weill concluded that "...after 10 years of these investigations, we have failed to demonstrate any adverse effect of MMMF [glass fibre] exposure on respiratory health. We have found workers in this industry to be generally healthy, without any detectable evidence of occupationally induced respiratory disease."

NAIMA joins our European colleagues in support of the existing body of scientific research that finds no cause and effect relation between exposure to fibreglass and lung disease or cancer in humans. Based on the current weight of scientific evidence, NAIMA remains confident that fibreglass products are safe to manufacture and install when the simple instructions outlined on product packages are followed.

KENNETH MENTZER
NAIMA, 44 Canal Center Plaza,
Suite 310, Alexandria, VA, USA.

Authors' reply

Sir,—We appreciate the opportunity to respond to Mentzer. His concern is well founded and NAIMA should be worried about the adverse human health effects of commercial rotary spun fibreglass.¹ Controverting the traditional fibre industry position he places the entire causal responsibility for abnormalities in the fibreglass workers on asbestos; not neglecting, of course, the contribution of cigarette smoking. He argues disingenuously that 40% of our workers with